The purpose of the current Phase 3 study is to confirm the effectiveness and safety of batoclimab in participants with generalized Myasthenia Gravis in 2 different doses of batoclimab compared to placebo.
Study is being conducted to ubderstand the effectiveness of ALXN2050 compared with placebo in the treatment of generalized MG (gMG) based on improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score
To assess the safety, tolerability and manufacturing feasibility of Descartes-08 in patients with generalized Myasthenia Gravis
The purpose of this study is to create a biorepository of blood samples form patients with myasthenia gravis that may be used with collaborators in the development of new therapeutics for myasthenia gravis (MG).
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against AChR (AChR+).
To test the effectiveness and safety of the drug ravulizumab in patients aged 6-18 years.
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
